TRIO Pharaceuticals Post Pitch Call

TRIO Pharaceuticals Presented at WAA's 11-Jul Life Sciences Pitch Event.

A post pitch call is on Monday, 22-Jul-2024 at 11am - 11:45am PT // 2pm - 2:45pm ET.

Please submit due diligence questions for Headache Sciences: TRIO Pharaceuticals_DD_Pitch Follow-up Questions_11-Jul-2024

Joining information will be sent upon registration.

Developing novel dual targeting antibody drugs to treat cancer by reducing toxicity and enhancing anti- tumor immunity.

PROBLEM: In absence of true tumor specific antigen increasing efficacy of treatment is impossible. We are solving the problem of increasing treatment efficacy in cancer.

SOLUTION: - Increasing anti- tumor immune response by removing immunosuppression in tumor by eliminating both cancer cells and immunosuppressor cells by using the first ever dual action ADC, TIE-ADC - Reducing toxicity by using first ever antibody drug, TRAILBody, that kills only cancer cells with no activity on normal cells thereby reducing toxicity.

• TRIO Pharmaceuticals Pitch Deck
• TRIO Pharmaceuticals Deal Terms
• TRIO Pharmaceuticals allocation for WAA: $250K
• TRIO Pharmaceuticals on Dealum
• 1-trio-pharma on Slack